We are redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients.
More About Us
The GRO Platform
The GRO platform expands the amino acid alphabet to overcome the limitations of protein therapeutics currently impeding the treatment of disease
We’re delivering on the long-awaited promise of protein therapeutics by solving the intrinsic limitations of proteins on potency, stability, and function. The GRO platform shortens development timelines and is the only system capable of seamlessly scaling production of NSAA (non-standard amino acid) proteins to meet clinical needs.
LEARN MORE
Our Pipeline
Today, we’re focused on our first two families of NSAA chemistries to drive our product pipeline
GRObio is advancing its first two families of NSAA chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side-effects of protein-based therapies.
LEARN MORE
Featured News
GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies
- Data represent promising new modalities for reversing autoimmune disease without immunosuppression and for eliminating anti-drug antibodies against immunogenic therapies BOSTON, September 27, 2023 - GRO Biosciences Inc. (“GRObio”), an…
Read More
proto.life: Recoding Life
proto.life: Scientists have created an organism that defies the rules of biology by using nonstandard amino acids. And you probably have some questions. Katia Tarasava, PhD, interviewed our CEO Dan…
Read More
Genetic Engineering & Biotechnology News: Noncanonical Amino Acids Inspire the Development of Novel Drugs
Julianna LeMieux, PhD, Senior Science Writer at Genetic Engineering & Biotechnology News, interviewed our CEO Dan Mandell, PhD, and describes how non-standard amino acids (NSAAs) enable a new class of…
Read More
